Tumor tissue oxygenation (pO2)

Tumor tissue oxygenation refers to the partial pressure of oxygen (pO2) within the tumor microenvironment, which is frequently characterized by hypoxia due to an imbalance between rapid cellular proliferation and dysfunctional vascularization (PMID: 27528212). This physiological state is a major driver of malignancy, as low oxygen levels stabilize Hypoxia-Inducible Factors (HIFs), which orchestrate a transcriptional program favoring angiogenesis, glycolytic metabolism, and immune evasion (PMID: 32814089). Furthermore, tumor hypoxia is a primary cause of resistance to radiotherapy and certain chemotherapies, as oxygen is required to fix DNA damage and facilitate drug efficacy (PMID: 21948245). Therapeutic approaches targeting this condition include hypoxia-activated prodrugs (HAPs) that are selectively toxic in anaerobic conditions and inhibitors of the HIF pathway (PMID: 25813477). Monitoring oxygenation through imaging tracers like [18F]FMISO or endogenous markers like Carbonic Anhydrase IX is critical for identifying patients who may benefit from hypoxia-targeted interventions.

Other names

Tumor hypoxiaIntratumoral oxygen tensionHypoxic tumor microenvironmentTumor pO2

Therapeutic strategies involve the use of hypoxia-activated prodrugs that undergo bioreductive activation in low-oxygen environments, small molecule inhibitors of the HIF transcription factor pathway, or methods to physically increase oxygen delivery to the tumor site.